Robert W. Baird Initiates Coverage on Tempus AI (NASDAQ:TEM)

Investment analysts at Robert W. Baird started coverage on shares of Tempus AI (NASDAQ:TEM) in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $59.00 price target on the stock. Robert W. Baird’s price objective indicates a potential upside of 5.06% from the stock’s current price.

TEM has been the topic of a number of other reports. HC Wainwright cut their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research note on Thursday, January 22nd. Piper Sandler cut their target price on Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Finally, BTIG Research increased their price target on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. Seven research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $84.64.

Tempus AI Stock Performance

Shares of Tempus AI stock opened at $56.16 on Tuesday. The stock has a market cap of $9.99 billion, a price-to-earnings ratio of -47.19 and a beta of 5.22. Tempus AI has a twelve month low of $36.22 and a twelve month high of $104.32. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The company’s fifty day moving average is $62.88 and its 200 day moving average is $73.48.

Insiders Place Their Bets

In other Tempus AI news, EVP Erik Phelps sold 1,302 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $67.42, for a total transaction of $87,780.84. Following the completion of the sale, the executive vice president directly owned 89,280 shares in the company, valued at $6,019,257.60. The trade was a 1.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO James William Rogers sold 19,966 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at approximately $8,143,500. The trade was a 15.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 544,188 shares of company stock valued at $37,163,496. 26.27% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC bought a new stake in Tempus AI in the 3rd quarter valued at $25,000. JPL Wealth Management LLC purchased a new stake in shares of Tempus AI in the third quarter valued at $26,000. GAMMA Investing LLC purchased a new position in shares of Tempus AI during the third quarter valued at approximately $28,000. Allworth Financial LP lifted its position in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after purchasing an additional 450 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new stake in Tempus AI in the 4th quarter valued at about $27,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus unveiled a new AI-powered cancer diagnostic algorithm, a product development that investors see as revenue and differentiation upside ahead of earnings. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Positive Sentiment: Tempus partnered with Median to add FDA-cleared eyonis LCS AI lung cancer screening to its Pixel imaging platform, expanding imaging capabilities and potential commercial uptake in screening workflows. Tempus AI & Median Partner to Add AI Lung Cancer Screening to Pixel
• Positive Sentiment: Robert W. Baird initiated coverage with an “outperform” rating and a $59 price target, providing a near-term bullish analyst catalyst and validation for institutional investors. Baird initiates coverage of Tempus AI (TEM) with outperform recommendation
• Neutral Sentiment: Q4 2025 earnings are a near-term catalyst (reporting Feb. 24 after market close); the event could amplify moves in either direction depending on guidance and margins. Why Tempus AI Stock Is Up Today — And What to Watch Before Next Week’s Earnings
• Neutral Sentiment: Analysts expect robust top-line growth (Zacks cites ~82.8% revenue growth expectations) but flag a premium valuation that could limit near-term upside if execution or guidance disappoints. Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
• Negative Sentiment: Valuation and analyst-target gaps after recent share weakness have been highlighted in research/coverage pieces, suggesting downside risk if the company misses growth or margin expectations; investors should watch guidance and margin commentary closely. Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness And Analyst Target Gap

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.